Fatty acid imaging of the heart

Current Cardiology Reports

Volumn 13, Issue 2, 2011, Pages 121-131

  Giedd, Kenneth N ^a   Bergmann, Steven R ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

methyl p 123I iodophenyl pentadecanoic acid (BMIPP); Cardiac metabolism; Fatty acid metabolism; Metabolic imaging; Positron emissions tomography; Single photon emission computed tomography

Indexed keywords

FATTY ACID; FLUORODEOXYGLUCOSE F 18; GLIMEPIRIDE; IODOFILTIC ACID I 123; METFORMIN; PALMITIC ACID C 11; PIOGLITAZONE;

CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETIC CARDIOMYOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FATTY ACID METABOLISM; GLOMERULUS FILTRATION RATE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART SCINTISCANNING; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; MYOCARDIAL PERFUSION IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PREDICTIVE VALUE; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DIABETIC CARDIOMYOPATHIES; FATTY ACIDS; FLUORODEOXYGLUCOSE F18; HEART DISEASES; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OBESITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79955826314     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0163-0     Document Type: Review

References (34)

1. Bergmann SR. Positron emission tomography of the heart. In: Gerson M, editor. Cardiac nuclear medicine. 3rd ed. New York: McGraw-Hill 1997. p. 67-299.
2. Lerch RA, Bergmann SR, Sobel BE. Delineation of myocardial fatty acid metabolism with positron emission tomography. In: Bergmann SR, Sobel BE, editors. Positron emission tomography of the heart. Mount Kisco (NY): Futura Publishing 1992. p. 129-52.
3. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis. 1989 Nov-Dec;32(3):217-38. (Pubitemid 19274897)
4. Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovascular Dis. 1981 Mar- Apr;23(5):321-36.
5. Lopaschuk GD, Collins-Nakai RL, Itoi T. Developmental changes in energy substrate use by the heart. Cardiovascular Research. 1992 Dec;26(12):1172-80. (Pubitemid 23010529)
6. Werner JC, Whitman V, Vary TC, Fripp RR, Musselman J, Schuler HG. Fatty acid and glucose utilization in isolated, working newborn pig hearts. Am J Physiol. 1983 Jan;244(1): E19-23.
7. Makinde AO, Kantor PF, Lopaschuk GD. Maturation of fatty acid and carbohydrate metabolism in the newborn heart. Mol Cell Biochem. 1998 Nov;188(1-2):49-56. (Pubitemid 28493317)
8. Jani S, Bergmann SR. Metabolic modulation of myocardial ischemia. Curr Cardiol Rep. 2006 Mar;8(2):123-30.
9. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: Potential for pharmacological interventions. Cardiovascular Res 1997 Feb;33(2):243-57. (Pubitemid 27072627)
10. Mitra B, Panja M. Myocardial metabolism: pharmacological manipulation in myocardial ischaemia. J Assoc Physicians India. 2005 Jun;53:552-60. (Pubitemid 41280053)
11. Bergmann SR. Imaging of myocardial fatty acid metabolism with PET. J Nucl Cardiol. 2007 May-Jun;14(3):S118-24.
12. Myears DW, Sobel BE, Bergmann SR. Substrate use in ischemic and reperfused canine myocardium: quantitative considerations. Am J Physiol. 1987 Jul;253(1 Pt 2):H107-14.
13. Schwaiger M, Schelbert HR, Elison D, et al. Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model. J Am Coll Cardiol. 1985 Aug;6(2):336-47. (Pubitemid 15048810)
14. Dilsizian V, Bateman TM, Bergmann SR, et al. Metabolic imaging with β-methyl-p-[123I]-iodophenyl-pentadecanoic acid indentifies ischemic memory after demand ischemia. Circulation. 2005 Oct;112(14):2169-74.
15. Bergmann SR, Lerch RA, Fox KA, et al. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med. 1982 Oct;73(4):573-81. (Pubitemid 12003292)
16. Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy. J Am Coll Cardiol 2009 Oct;54(16):1524-32. This is a multimodality imaging study showing no direct relation between cardiac diastolic dysfunction and parameters of myocardial metabolism in men with uncomplicated type 2 diabetes mellitus.
17. Gropler RJ. Radionuclide imaging of myocardial metabolism. Circ Cardiovasc Imaging. 2010 Mar;3(2):211-22. This is a comprehensive review of MVO2 and carbohydrate and fatty acid metabolic imaging using magnetic resonance spectroscopy, PET, and SPECT.
18. Sugden MC, Holness MJ. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab. 2003 May;284(5):E855-62.
19. Dilsizian V, Fink JC. Deleterious effect of altered myocardial fatty acid metabolism in kidney disease. Editorial Comment. J Am Coll Cardiol. 2008 Jan;51(2):146-8. This editorial comment summarizes the cardiac derangements associated with CKD, the associated histopathologic and metabolic correlates, and the use of BMIPP imaging in patients with renal disease.
20. Fink JC, Lodge MA, Smith MF, et al. Pre-clinical myocardial alterations in chronic kidney disease. Cardiology. 2010 Jan;116 (3):160-7. This is a pilot study of the feasibility of using dynamic FDG PET imaging to assess myocardial metabolic changes in patients with CKD.
21. 11C-palmitate. J Nucl Cardiol. 2009 May-Jun;16(3):411-21.
22. Kim DH, Choe YS, Choi JY, Choi Y, Lee KH, Kim BT. 17-[4- (2-[18F]-Fluoroethyl)-1H-1,2,3-triazol-1-yl]-6-thia-heptadecanoic acid: A potential radiotracer for the evaluation of myocardial fatty acid metabolism. Bioconjugate Chem. 2009 Jun;20(6):1139-45.
23. 123I]-iodophenyl-pentadecanoic acid (BMIPP) imaging: a metaanalysis. J Nucl Cariol. 2008 May-Jun;15(3):345-52. This is a meta-analysis of seven studies that showed the diagnostic performance of BMIPP metabolic imaging compares favorably with that of myocardial perfusion imaging in patients with a high prevalence of CAD.
24. Inaba Y, Bergmann SR. Prognostic value of metabolic imaging with BMIPP in the spectrum of coronary artery disease: A systematic review. J Nucl Cardiol. 2010 Jan-Feb;17(1):61-70. This is a meta-analysis of 11 studies. Among patients with a suspected ACS in whom myocardial infarction was ruled out, the negative predictive value of a normal BMIPP study for hard events was 99% over 3.5 years; among patients with acute infarction, the relative risk of a large BMIPP defect was 2.8 for the prediction of death and 3.9 for prediction of hard events.
25. Kontos MC, Dilsizian V, Weiland F, et al. Iodofiltic acid 123I (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter trial. J Am Coll Cardiol 2010 Jul;56 (4):290-9.
26. Biswas SK, Sarai M, Yamada A, et al. The washout rate of 123I BMIPP and the evolution of left ventricular function in patients with successfully reperfused ST-segment elevation myocardial infarction: comparisons with echocardiography. Int J Cardiovasc Imaging. 2010 Jan;26:155-64.
27. 18F-FDG uptake as a surrogate marker for antecedent ischemia. Invited perspective. J Nucl Med. 2008 Dec;49 (12):1909-11.
28. van der Meer RW, Rijzewijk LJ, de Jong HWAM, et al. Pioglitazone improves cardiac function and alters cardiac substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with wellcontrolled type 2 diabetes. Circulation 2009 Apr;119:2069-77. This is a study showing no association between alterations in myocardial FA metabolism, glucose uptake, and high-energy metabolism, and improvements in diastolic function in men with type 2 diabetes mellitus treated with pioglitazone.
29. Rijzewijk LJ, Jonker TJ, van der Meer RW, et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010 Jul;56(3):225-33.
30. Viljanen AP, Karmi A, Borra R, et al. Effect of caloric restriction on myocardial fatty acid uptake, left ventricular mass, and cardiac work in obese adults. Am J Cardiol. 2009 Jun; 103 (12):1721-6. This is a study showing that weight loss in obese patients leads to a decrease in myocardial FA uptake and reductions in myocardial mass and cardiac work.
31. Dilsizian V, Eckelman WC, Loredo ML, Jagoda EM, Shirani J. Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique. J Nucl Med. 2007 Feb;48(2):182-7. (Pubitemid 47555341)
32. Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients bymyocardial fatty acid imaging. J Am Col Cardiol. 2008 Jan;51(2):139-45.
33. Sato A,Aonuma K, Nozato T, et al. Stunnedmyocardium in transient left ventricular apical ballooning: a serial study of dual 123I-BMIPP and 201Tl SPECT. J Nucl Cardiol. 2008 Sep-Oct;15(5):671-9.
34. Mahmarian J: Myocardial metabolic imaging in the acute care setting. J Nucl Cardiol 2007, 14:S139-S144.